CN116211938A - Lentinus edodes strain fermentation composition and preparation method and application thereof - Google Patents

Lentinus edodes strain fermentation composition and preparation method and application thereof Download PDF

Info

Publication number
CN116211938A
CN116211938A CN202310203233.0A CN202310203233A CN116211938A CN 116211938 A CN116211938 A CN 116211938A CN 202310203233 A CN202310203233 A CN 202310203233A CN 116211938 A CN116211938 A CN 116211938A
Authority
CN
China
Prior art keywords
parts
red
dispersion liquid
cranberry
medlar
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202310203233.0A
Other languages
Chinese (zh)
Inventor
袁岚
马志民
徐连明
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wuxi Kangneng Teyi Food Technology Co ltd
Original Assignee
Wuxi Kangneng Teyi Food Technology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wuxi Kangneng Teyi Food Technology Co ltd filed Critical Wuxi Kangneng Teyi Food Technology Co ltd
Priority to CN202310203233.0A priority Critical patent/CN116211938A/en
Publication of CN116211938A publication Critical patent/CN116211938A/en
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/55—Linaceae (Flax family), e.g. Linum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A61K36/07—Basidiomycota, e.g. Cryptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
    • A61K36/258—Panax (ginseng)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/45—Ericaceae or Vacciniaceae (Heath or Blueberry family), e.g. blueberry, cranberry or bilberry
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/72—Rhamnaceae (Buckthorn family), e.g. buckthorn, chewstick or umbrella-tree
    • A61K36/725—Ziziphus, e.g. jujube
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
    • A61K36/738—Rosa (rose)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
    • A61K36/815—Lycium (desert-thorn)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P1/00—Preparation of compounds or compositions, not provided for in groups C12P3/00 - C12P39/00, by using microorganisms or enzymes
    • C12P1/02—Preparation of compounds or compositions, not provided for in groups C12P3/00 - C12P39/00, by using microorganisms or enzymes by using fungi
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/10—Preparation or pretreatment of starting material
    • A61K2236/19—Preparation or pretreatment of starting material involving fermentation using yeast, bacteria or both; enzymatic treatment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/645—Fungi ; Processes using fungi
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02W—CLIMATE CHANGE MITIGATION TECHNOLOGIES RELATED TO WASTEWATER TREATMENT OR WASTE MANAGEMENT
    • Y02W30/00—Technologies for solid waste management
    • Y02W30/40—Bio-organic fraction processing; Production of fertilisers from the organic fraction of waste or refuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Medical Informatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Botany (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

The invention provides a mushroom strain fermentation composition, a preparation method and application thereof, and belongs to the field of mushroom strain application. The material is prepared from the following raw materials in parts by weight: 20-60 parts of flaxseed concentrated powder, 10-30 parts of red rose with heavy petals, 10-30 parts of gamma-aminobutyric acid, 10-55 parts of red ginseng, 10-55 parts of red date, 10-55 parts of medlar, 10-55 parts of cranberry and 20-100 parts of mushroom strain fermentation culture solution. The traditional Chinese medicine has the effects of enriching and activating blood, tonifying qi and nourishing liver, improving metabolism capacity, promoting microcirculation in a body, accelerating internal circulation, and further conditioning female endocrine dyscrasia, so that the syndrome caused by female estrogen reduction is improved.

Description

Lentinus edodes strain fermentation composition and preparation method and application thereof
Technical Field
The invention relates to the field of application of mushroom strains, in particular to a mushroom strain fermentation composition, a preparation method and application thereof.
Background
The normal human body is regulated by endocrine system and nervous system together, wherein the endocrine system is involved in regulating metabolism, growth and development, reproduction and aging and other physiological activities of human body by secreting various hormones, and the endocrine system cooperates with various biological enzymes to maintain the relative stability of the environment in human body so as to adapt to complex and changeable changes in vitro and in vivo. When the endocrine system of the human body is disturbed, the corresponding clinical manifestation is caused, especially, the female has special physiological processes such as menstruation, leucorrhea, fetus, birth and the like, and the endocrine disturbance is more likely to occur in daily life under the double pressure of work and families, thereby causing various gynecological diseases such as irregular menstruation, dysmenorrhea, amenorrhea, hyperplasia of mammary glands and the like.
According to traditional Chinese medicine, endocrine dyscrasia is a manifestation of yin deficiency and is caused by qi and blood stasis, and qi and blood stasis stagnation in the body, vein obstruction, invasion of external toxin, postpartum lochia and the like can possibly cause qi and blood stasis, so that qi and blood are unobstructed, essence and blood are nourished the whole body, blood circulation is promoted, and comprehensive conditioning is performed from inside to outside.
The existing gynecological medicine has only a single function due to the limitation of the formula, and the existing gynecological medicine for treating gynecological diseases is matched with chemicals with few side effects, and the recurrence condition in a short period is common although the effect is quick. The pure traditional Chinese medicine prescription is used for the best treatment, but the treatment course of the pure traditional Chinese medicine gynecological medicine is very long and cannot be radically cured; and the process for decocting the traditional Chinese medicine is complex, the time is limited, and the efficient production cannot be realized.
Disclosure of Invention
In order to solve the problems, the invention provides a mushroom strain fermentation composition, a preparation method and application thereof, and the mushroom strain fermentation composition has the effects of enriching and activating blood, tonifying qi and nourishing liver, improving metabolism capacity, promoting microcirculation in a body, accelerating internal circulation, and further conditioning female endocrine dyscrasia to improve syndrome caused by female estrogen reduction.
In order to achieve the above object, the present invention provides the following technical solutions:
the invention provides a mushroom strain fermentation composition which is prepared from the following raw materials in parts by weight:
20-60 parts of flaxseed concentrated powder, 10-30 parts of red rose with heavy petals, 10-30 parts of gamma-aminobutyric acid, 10-55 parts of red ginseng, 10-55 parts of red date, 10-55 parts of medlar, 10-55 parts of cranberry and 20-100 parts of mushroom strain fermentation culture solution.
Preferably, the material is prepared from the following raw materials in parts by weight:
30-50 parts of flaxseed concentrated powder, 15-25 parts of red rose with heavy petals, 15-25 parts of gamma-aminobutyric acid, 22-45 parts of red ginseng, 22-45 parts of red date, 22-45 parts of medlar, 22-45 parts of cranberry and 44-80 parts of mushroom strain fermentation culture solution.
Preferably, the material is prepared from the following raw materials in parts by weight:
40 parts of flaxseed concentrated powder, 20 parts of red rose with heavy petals, 20 parts of gamma-aminobutyric acid, 30 parts of red ginseng, 30 parts of red date, 30 parts of medlar, 30 parts of cranberry and 60 parts of mushroom strain fermentation culture solution.
Preferably, the red rose flower with heavy petals is red rose pollen with heavy petals;
the red ginseng is red ginseng powder;
the red dates are red date powder;
the medlar is medlar powder;
the cranberry is cranberry powder;
the fungus content in the mushroom strain fermentation culture solution is 1x10 4 -1x10 5 /ml.
The invention also provides a preparation method of the lentinus edodes strain fermentation composition, which comprises the following steps:
1) Dispersing mushroom strains into water to obtain mushroom strain dispersion liquid, and sequentially carrying out slant culture, shake flask culture, seed culture, propagation culture and fermentation culture on the mushroom strain dispersion liquid to obtain mushroom strain fermentation culture liquid;
2) The linseed concentrated powder, the red rose with heavy petals, the gamma-aminobutyric acid, the red ginseng, the red jujube, the medlar and the cranberry are respectively dispersed in water to obtain a linseed dispersion liquid, a red rose with heavy petals, a gamma-aminobutyric acid dispersion liquid, a red ginseng dispersion liquid, a red jujube dispersion liquid, a medlar dispersion liquid and a cranberry dispersion liquid;
3) Mixing the lentinus edodes strain fermentation culture solution obtained in the step 1) with the flaxseed dispersion liquid, the red rose dispersion liquid with heavy petals, the gamma-aminobutyric acid dispersion liquid, the red ginseng dispersion liquid, the red date dispersion liquid, the medlar dispersion liquid and the cranberry dispersion liquid obtained in the step 2), standing for reaction, centrifuging to obtain a supernatant, and drying the supernatant to obtain the lentinus edodes strain fermentation composition;
the steps 1) and 2) are defined in no time sequence.
Preferably, the conditions of the standing reaction in the step 3) include: the temperature is 30-37 ℃ and the time is 12-16 h.
Preferably, the volume ratio of the lentinus edodes strain fermentation culture solution in the step 3) to the total volume of the flaxseed dispersion liquid, the red rose dispersion liquid, the gamma-aminobutyric acid dispersion liquid, the red ginseng dispersion liquid, the red date dispersion liquid, the medlar dispersion liquid and the cranberry dispersion liquid is 9:1-3.
Preferably, the mass ratio of the flaxseed concentrated powder, the red rose with heavy petals, the gamma-aminobutyric acid, the red ginseng, the red dates, the medlar and the cranberry to the water in the step 2) is 1:2-4.
Preferably, the activity of beta-glucosidase in the mushroom strain fermentation culture solution in the step 1) is not less than 1200U/g.
The invention also provides application of the lentinus edodes strain fermentation composition in preparation of medicines for female endocrine dyscrasia.
The beneficial effects of the invention are as follows:
the fermentation composition provided by the invention can respectively convert the coumaryl-sebaceous glucosides (SecoisolariciresinolDiGlucoside, SDG) in the flaxseed lignans into coumaryl-sebaceous glucosides (SECO) by utilizing the desugaring effect of beta-glucosidase in the culture solution obtained after the fermentation of the lentinula edodes strain, and the SECO is easier to absorb than the SDG, so that the bioavailability of the flaxseed lignans is greatly improved from 15% to 75%; under the action of beta-glucosidase, various glycosides or aglycones in other raw materials including red rose, gamma-aminobutyric acid, red ginseng, red date, medlar and cranberry raw materials can be converted into aglycones, the aglycones are easy to be absorbed by human bodies, and the bioavailability of active ingredients in the raw materials is further promoted to be obviously improved.
The traditional Chinese medicine has the effects of enriching and activating blood, tonifying qi and nourishing liver, improving metabolism capacity, promoting microcirculation in a body, accelerating internal circulation, and further conditioning female endocrine dyscrasia, so that the syndrome caused by female estrogen reduction is improved.
Drawings
FIG. 1 is a schematic representation of the absorption and metabolism of lignans in vivo; (ζ) beta-glucosidase Activity, square without pH value, in the present invention, the beta-glucosidase Activity in the Lentinus Edodes seed fermentation broth is preferably not less than 1200U/g
FIG. 2 shows the change in beta-glucosidase activity in a Lentinus edodes seed fermentation broth; SECO-DGandSECO incubatedwith (A) NFLEC; (B) flecotainedfrom the culture; peaks 1.SECO-DG,2, SECO;
FIG. 3 is a graph showing the variation of SECO in urine of healthy subjects taking an unfermented/fermented composition; the urine was collected 0,1,3,5,7,24 hours after administration and SECO content was determined by HPLC the differences between groups were checked by Student's st-test (< 0.01; < 0.05); group 1 (o) 50ML of unfermented composition (NFLEC) was administered to healthy subjects (5); group 2 (≡), 50ML of fermented composition (Fermentedlentinusedodes complex, FLEC) was administered to healthy subjects (5 persons).
Detailed Description
A lentinus edodes strain fermentation composition is prepared from the following raw materials in parts by weight: 20-60 parts of flaxseed concentrated powder, 10-30 parts of red rose with heavy petals, 10-30 parts of gamma-aminobutyric acid, 10-55 parts of red ginseng, 10-55 parts of red date powder, 10-55 parts of medlar, 10-55 parts of cranberry and 20-100 parts of mushroom strain fermentation culture solution.
The lentinus edodes strain fermentation composition provided by the invention comprises 20-60 parts by weight of flaxseed concentrated powder, preferably 30-50 parts by weight, and more preferably 40 parts by weight. In the present invention, the particle size of the linseed concentrated powder is preferably 0.25 to 0.15mm. In the invention, the flaxseed concentrate powder is purchased from a self-produced raw material of the Wuxi kang energy company. In the invention, the flaxseed concentrate powder, flax (Linum usitatissimum L) is also called as a flax, belongs to the genus flaxseed of the family flaxseed, and is one of the oldest crops. Flaxseed is the seed of flax, the husk is hard and Flaxseed Lignans (Flaxseed Lignans) are mainly present in the husk part. Linseed lignan is also known as phytoestrogen because its chemical structure is very similar to that of human estrogen. Bidirectional regulation of estrogen levels in humans by linseed lignans: A. estrogenic effects: the chemical structure of the linseed lignan SDG is very similar to that of human estrogen, and when the estrogen level in the human body is low, the SDG is converted into intestinal lipid (END) and intestinal glycol (ENL) after being ingested. END and ENL are similar in structure to estrogens, with antioxidant activity and weak estrogenic effects. The effect of in vivo estrogens can be balanced by the connection with the receptor, and the climacteric symptoms can be relieved to a certain extent. B. Inhibition of estrogenic effects: END and ENL can also act as antiestrogenic molecules when the level of estrogen in the body is deceived to be high, because the structure is very similar to the main form of estrogen, but does not have the exact same estrogenic effect, and when combined with some breast cell receptors with active proliferation, it acts as a site rather than function, preventing the estrogenic effect, thus inhibiting the growth of such cells. Chemical composition of linseed lignans: linseed lignans are natural products of phenylpropanoids metabolism. The highest content in flaxseed is coumarins glucoside (Secoisolariciresinol DiGlucoside, SDG). The aglycone of the diglycoside SDG is sebaceous isovanillin (SECO). SDG is also not present in whole in free form in flaxseed, and part of SDG is covalently bound to 3-hydroxy-3-methyl-glutaric acid (HMGA) via ester linkages, cross-linking with 4 HMGA molecules on average every 5 SDG molecules, yielding oligomers of about 4000 relative molecular mass. A metabolite of linseed lignans: linseed lignans are converted to various metabolites, including Enterolactone (ENL) and Enterodiol (ED)) and their phase II metabolites, such as glucuronic acid conjugates. The conversion of diisohydroxy resinol diglucoside (SDG) of linseed lignan can be divided into four catalytic reactions, in turn O-deglycosylation (SDG to its aglycone, SECO), O-demethylation (SECO to 2, 3-bis (3' -hydroxybenzyl) butyrolactone/2, 3-bis (3, 4-dihydroxybenzyl) butane-1, 4-diol), dehydrogenation (2, 3-bis (3, 4-dihydroxybenzyl) butane-1, 4-diol to ED) and dihydroxylation (ED to ENL).
The lentinus edodes strain fermentation composition provided by the invention comprises 10-30 parts by weight of red rose flowers with heavy petals, preferably 15-25 parts by weight, and more preferably 20 parts by weight. The powder prepared by the red rose flowers with heavy petals is preferably reused, and the particle size of the red rose flowers with heavy petals is preferably 0.25-0.15 mm. In the invention, the heavy-petal red rose is the representative of Chinese traditional rose, and the variety has large flowers, bright color, rich fragrance, multiple petals and thick petals, the single flower diameter reaches 8 cm, the single flower weight can reach 6 g, and becomes a main variety for production and cultivation. The red rose with heavy petals is the only edible rose for me. The traditional Chinese medicine holds that the rose has sweet and slightly bitter taste and warm nature, and the most obvious effects are regulating qi, resolving stagnation, promoting blood circulation, dispelling blood stasis, regulating menstruation and relieving pain. In addition, the property of the rose is very mild, and the rose can warm and nourish heart and liver blood vessels of people and Shu Fa in-vivo qi stagnation, so that the rose has the effects of calming, soothing and anti-depression. Women often have emotional dysphoria before menstruation or during menstruation, and the roses can play a role in regulating. At present, the pressure of work and life is greater and greater, and even if not in menstrual period, the rose can be drunk more, and the emotion is calmed and stabilized. The flos Rosae Rugosae is rich in vitamin A, C, B, E, K and tannin, and can improve endocrine disturbance, and is helpful for relieving fatigue and wound healing. Regulating qi and blood, regulating female physiological problems, promoting blood circulation, caring skin, regulating menstruation, promoting urination, relieving gastrointestinal nerves, preventing wrinkles and frostbite, and caring skin. When the body is tired and ache, the massage is quite suitable. The rose buds are made into dry flowers, 5 to 7 flowers are used each time, a small pinch of green tea with tender tips is matched, three red dates are added (to be stoned), and the dried flowers can be drunk after being boiled water for each day, so that heart fire can be removed, the vigor is kept, the vigor of your is increased, and the dried flowers can be drunk for a long time, so that your appearance is white, the youth is bright and the youth is beautiful. Conditioning the body: the rose tea has the advantages of mild property, mild emotion relieving, endocrine balancing, blood and qi replenishing, beauty and skin care, liver and stomach conditioning, fatigue elimination, physique improvement, faint and elegant rose tea taste, emotion relieving, depression relieving, endocrine disturbance relieving, waist soreness and back pain relieving, fatigue elimination and wound healing, skin nourishing, skin care, blood circulation promoting, liver protection, stomach harmonizing, liver nourishing, fatigue elimination and blood circulation promoting effects. Can be used for treating chronic gastritis and hepatitis. Liver soothing, qi stagnation relieving, qi and blood regulating: the Chinese medicinal composition has the effects of soothing liver, relieving depression, strengthening spleen, reducing pathogenic fire, removing blood stasis and the like, can treat abdominal pain, cold stagnation in stomach, smooth circulation of blood and qi, tranquillization, relaxing bowels, reducing pathogenic fire and qi, can regulate blood and qi, promote blood circulation, remove blood stasis, alleviate emotion, regulate endocrine, regulate qi and blood and regulate female physiological problems; beautifying and young keeping: most importantly, the beverage has the effects of maintaining beauty and keeping young, can remove black spots on skin after being drunk frequently, enables the skin to be tender and natural, and is helpful for preventing wrinkles. Can improve physique, reduce weight due to stagnation of liver-qi, and promote weight loss; has effects of enlarging breast and regulating menstruation; it also has effects in loosening bowel to relieve constipation, caring skin, and reducing weight.
The lentinus edodes strain fermentation composition provided by the invention comprises 10-30 parts by weight of gamma-aminobutyric acid, preferably 15-25 parts by weight, and more preferably 20 parts by weight. In the invention, the gamma-aminobutyric acid improves the sleep state, and the physiological activity mainly has the functions of tranquilizing nerves, resisting anxiety, reducing blood pressure, reducing blood ammonia, improving brain activity, promoting ethanol metabolism, preventing skin aging, preventing arteriosclerosis, reducing weight and the like.
The lentinus edodes strain fermentation composition provided by the invention comprises 10-55 parts by weight of red ginseng, preferably 22-45 parts by weight, and more preferably 30 parts by weight. In the invention, the red ginseng is preferably red ginseng powder, and the particle size of the red ginseng powder is preferably 0.25-0.15 mm. In the invention, the main component of the red ginseng for improving qi and blood and resisting fatigue is triterpenoid saponin, and the red ginseng also contains volatile oil, polysaccharide, amino acid, trace elements, polypeptide and the like. Triterpene saponin and polysaccharide of Ginseng radix Rubri are main pharmacological active ingredients. Efficacy: the red ginseng is a cooked product of ginseng, has the effects of invigorating primordial qi, tonifying spleen and lung, promoting the production of body fluid and soothing nerves, has milder drug property than the ginseng, and is used for treating deficiency of qi and blood, hand and foot warmth, dizziness and lassitude, limb weakness, fatigue, shortness of breath and shortness of breath, cold feeling in stomach, long-term diarrhea, insomnia and dreaminess, impotence and frequent urination and the like.
The lentinus edodes strain fermentation composition provided by the invention comprises 10-55 parts by weight of red dates, preferably 22-45 parts by weight of red dates, and more preferably 30 parts by weight of red dates. In the invention, the red date is preferably red date powder, and the particle size of the red date powder is preferably 0.25-0.15 mm. In the invention, the red date improves hematopoietic function, and has Wen Weigan properties, which contains protein, fat, sugar, calcium, phosphorus, iron, magnesium, and abundant vitamin A, vitamin C, vitamin B1, vitamin B2, and carotene. Nourishing spleen and stomach, replenishing qi to invigorate spleen, nourishing blood to tranquilize, promoting qi and blood biochemical circulation, invigorating spleen and replenishing qi, nourishing blood to tranquillize, delaying aging and stimulating appetite.
The lentinus edodes strain fermentation composition provided by the invention comprises 10-55 parts by weight of medlar, preferably 22-45 parts by weight, and more preferably 30 parts by weight. In the present invention, the wolfberry is preferably wolfberry powder, and the particle size of the wolfberry powder is preferably 0.25-0.15 mm. In the invention, the medlar improves hematopoietic function and has the following nutritional ingredients: the main components of the medlar extract are as follows: lycium barbarum polysaccharides (Lycium barbarum polysaccharides) have molecular weight of 22-25 kD and are composed of 6 monosaccharide components including arabinose, glucose, galactose, mannose, xylose and rhamnose. Fructus Lycii also contains abundant carotene, vitamin A, vitamin C, vitamin E, calcium, ferrum, magnesium, phosphorus, and carbohydrate. Efficacy: has the main effects of enhancing immunity and regulating immunity, promoting hematopoiesis, reducing blood lipid, resisting fatty liver, resisting tumor, and resisting aging. Can replenish essence, improve eyesight, nourish liver and kidney, and is suitable for people with consumptive disease, essence deficiency, soreness of waist and knees, visual function decline, dizziness and tinnitus.
The lentinula edodes strain fermentation composition provided by the invention comprises 10-55 parts by weight of cranberry, preferably 22-45 parts by weight, and more preferably 30 parts by weight. In the present invention, the cranberry is preferably cranberry powder, and the particle size of the cranberry powder is preferably 0.25-0.15 mm. In the invention, the cranberry has the functions of antioxidation and urinary tract anti-infection, and the nutrition components are as follows: the cranberry contains various flavonols such as procyanidine, ellagic acid, phenolic acid, resveratrol, hyperoside, quercetin, myricetin, etc. Efficacy: the cranberry has the most unique effects of effectively preventing Urinary Tract Infection (UTI) and inhibiting helicobacter pylori infection, and has good effects of preventing gastric ulcer, gastric cancer and duodenal ulcer. Can inhibit oxidation of low density lipoprotein-cholesterol, reduce triglyceride level in blood, and prevent cardiovascular and cerebrovascular diseases such as atherosclerosis.
The lentinus edodes strain fermentation composition provided by the invention comprises 20-100 parts by weight of lentinus edodes strain fermentation culture solution, preferably 44-80 parts by weight, and more preferably 60 parts by weight. In the invention, the activity of beta-glucosidase in the mushroom strain fermentation culture solution is preferably not less than 1200U/g. In the invention, the mushroom Strain is purchased from a national Strain resource library, and the Strain Number/Strain Number is CCTCC NF20083277, chinese Name/Chinese Name mushroom; generic name/genome Lentinul.
The invention provides a preparation method of the lentinus edodes strain fermentation composition, which comprises the following steps:
1) Dispersing the mushroom strain in water to obtain a mushroom strain dispersion liquid, and sequentially carrying out slant culture, shake flask culture, seed culture, propagation culture and fermentation culture on the mushroom strain dispersion liquid to obtain a mushroom strain fermentation culture liquid;
2) The linseed concentrated powder, the red rose with heavy petals, the gamma-aminobutyric acid, the red ginseng, the red jujube, the medlar and the cranberry are respectively dispersed in water to obtain a linseed dispersion liquid, a red rose with heavy petals, a gamma-aminobutyric acid dispersion liquid, a red ginseng dispersion liquid, a red jujube dispersion liquid, a medlar dispersion liquid and a cranberry dispersion liquid;
3) Mixing the lentinus edodes strain fermentation culture solution obtained in the step 1) with the flaxseed dispersion liquid, the red rose dispersion liquid with heavy petals, the gamma-aminobutyric acid dispersion liquid, the red ginseng dispersion liquid, the red date dispersion liquid, the medlar dispersion liquid and the cranberry dispersion liquid obtained in the step 2), standing for reaction, centrifuging to obtain a supernatant, and drying the supernatant to obtain the lentinus edodes strain fermentation composition;
the steps 1) and 2) are defined in no time sequence.
The invention disperses the mushroom strain to obtain mushroom strain dispersion liquid, and sequentially carries out slant culture, shake flask culture, seed culture, propagation culture and fermentation culture on the mushroom strain dispersion liquid to obtain mushroom strain fermentation culture liquid.
In the invention, the volume ratio of the mushroom strain to the water is 0.1-1.0:10.
In the invention, the composition of the slant culture medium used for slant culture preferably comprises 2-4wt% of glucose, 0.2-0.4wt% of peptone, 0.4-0.8wt% of bran, 0.1-0.3wt% of potassium dihydrogen phosphate, 0.03-0.05wt% of magnesium sulfate, 0.1-0.3wt% of histidine, 2-4wt% of agar and pH:5.0 to 7.5, wherein the solvent is water; sterilization conditions: 0.1MPa,30-40 min. In the present invention, the conditions of the slant culture preferably include: inoculating the mushroom strain dispersion liquid to a slant culture medium, and culturing for 7-9 days at the constant temperature of 15-20 ℃ with the inoculation amount of 2.52.5-5 wt%.
In the invention, the shake flask culture medium used for shake flask culture preferably comprises 1-5wt% of glucose, 0.2-0.4wt% of peptone, 0.4-0.6wt% of bran, 0.1-0.3wt% of potassium dihydrogen phosphate, 0.03-0.05wt% of magnesium sulfate, 0.03-0.05wt% of zinc sulfate, 0.1-0.3wt% of histidine, 10.05-0.1wt% of vitamin B, and pH:5.0 to 7.5, and the solvent is water. In the present invention, the conditions of shake flask culture preferably include: under aseptic condition, inoculating cultured slant strain into shake flask culture medium, and culturing in shaking table at 15-20deg.C under illumination for 7-9 days; the oscillating frequency of the reciprocating shaking table is 135 times/min, and the red light irradiation with the wavelength of 622-760 nm is used in the whole shaking flask culture process, and the inoculation amount is 1-10 ml.
In the present invention, the composition of the culture medium used for the seed culture is preferably: 1-2wt% of hot pressed bean cake powder, 1-2wt% of glucose, 1-2wt% of sucrose, 0.1-0.2wt% of monopotassium phosphate, 0.05wt% of magnesium sulfate, 0.05wt% of zinc sulfate, 0.1wt% of histidine, 0.02wt% of vitamin B1, 0.1wt% of soybean oil, 0.05wt% of adenine, pH:5.0 to 7.5, wherein the solvent is water; under the aseptic condition, inoculating the strain cultured by shaking bottle into a seed tank according to the inoculation amount of 3% by adopting a differential pressure method, and at the temperature of 16 ℃, the tank pressure is 0.02MPa, and the ventilation is 1:0.5 And (v/v.min) standing and culturing for 4-5 days.
In the present invention, the composition of the medium used for the propagation culture is preferably: 1-2wt% of hot pressed bean cake powder, 1-2wt% of glucose, 1-2wt% of sucrose, 0.1wt% of monopotassium phosphate, 0.04wt% of magnesium sulfate, 0.03wt% of zinc sulfate, 0.1wt% of histidine, 0.1wt% of vitamin B1, 0.2wt% of soybean oil, 0.05wt% of adenine and 0.05wt% of uracil, and pH:5.0 to 7.5, wherein the solvent is water; under aseptic conditions, inoculating the strain cultured by the seeds into a propagation tank according to the inoculation amount of 9% by adopting a differential pressure method; at a temperature of 16 ℃, a tank pressure of 0.02MPa, a ventilation of 1:0.15 And (v/v.min) standing and culturing for 4-5 days.
In the present invention, the composition of the medium used for the fermentation culture is preferably: 1-3wt% of hot pressed soybean cake powder, 1wt% of glucose, 1wt% of sucrose, 0.2wt% of monopotassium phosphate, 0.04wt% of magnesium sulfate, 0.04wt% of zinc sulfate, 0.2wt% of histidine, 0.2wt% of vitamin B1, 0.2wt% of soybean oil, 0.05wt% of adenine, 0.05wt% of uracil, pH:5.0 to 7.5, wherein the solvent is water; under aseptic conditions, inoculating the cultured strain into a fermentation tank according to 5% of inoculum size by adopting a differential pressure method; at a temperature of 16 ℃, a tank pressure of 0.02MPa, a ventilation of 1:0.75 (v/v.min) and culturing for 4-5 days under stirring at 40 rpm. In the invention, the activity of beta-glucosidase in the mushroom strain fermentation culture solution is preferably not less than 1200U/g. In the present invention, beta-glucosidase is also called beta-D-glucosidase glucohydrolase, belongs to cellulase, is an important component in cellulolytic enzyme system, and can hydrolyze beta-D-glucose bond combined with terminal non-reducing property and release beta-D-glucose and corresponding ligand. Beta-glucosidase is also a hydrolase with important physiological functions, can catalyze oxygen-affinity glycosyl transfer, can catalyze glycosidic bonds in aryl, amino or alkyl-beta-D-glycoside and raw green glycoside, short-chain oligosaccharide and disaccharide under certain conditions, and can generate reverse hydrolysis reaction under certain conditions to generate a plurality of new glycosides. According to this principle, SDG of secoisolariciresinol diglucoside can be converted into SECO by this desugaring action of beta-glucosidase during industrial processing. Thus, the absorptivity and the conversion speed of the linseed lignans in the body are greatly improved, and the linseed lignans have higher biological activity.
The invention respectively disperses the linseed concentrated powder, the red rose with heavy petals, the gamma-aminobutyric acid, the red ginseng, the red date, the medlar and the cranberry to obtain a linseed dispersion liquid, a red rose with heavy petals, a gamma-aminobutyric acid dispersion liquid, a red ginseng dispersion liquid, a red date dispersion liquid, a medlar dispersion liquid and a cranberry dispersion liquid. In the invention, the mass ratio of the linseed concentrated powder, the red rose with heavy petals, the gamma-aminobutyric acid, the red ginseng, the red dates, the medlar, the cranberry and the water is preferably 1:2-4.
Mixing the obtained lentinus edodes strain fermentation culture solution with the obtained flaxseed dispersion liquid, the obtained red rose dispersion liquid, the obtained gamma-aminobutyric acid dispersion liquid, the obtained red ginseng dispersion liquid, the obtained red date dispersion liquid, the obtained medlar dispersion liquid and the obtained cranberry dispersion liquid, standing for reaction, centrifuging to obtain a supernatant, and drying the supernatant to obtain the lentinus edodes strain fermentation composition.
In the invention, the volume ratio of the lentinus edodes strain fermentation culture solution to the total volume of the flaxseed dispersion liquid, the red rose dispersion liquid, the gamma-aminobutyric acid dispersion liquid, the red ginseng dispersion liquid, the red date dispersion liquid, the medlar dispersion liquid and the cranberry dispersion liquid is preferably 9:1-3. In the invention, the volume ratio of the flaxseed dispersion liquid, the red rose dispersion liquid with heavy petals, the gamma-aminobutyric acid dispersion liquid, the red ginseng dispersion liquid, the red date dispersion liquid, the medlar dispersion liquid and the cranberry dispersion liquid is preferably 3:1:1:1:1:1:1.
In the present invention, the conditions of the stationary reaction preferably include: the temperature is 30-37 ℃ and the time is 12-16 h. In the present invention, the conditions of the centrifugation preferably include: the rotating speed is 500-600 rpm, and the time is 20-30 min. In the present invention, the drying conditions preferably include: the temperature is 85-130 ℃ and the time is 10-15 min. In the present invention, the particle size of the lentinus edodes seed fermentation composition is preferably 50-100 mesh.
The invention also provides application of the lentinus edodes strain fermentation composition in preparation of medicines for female endocrine dyscrasia.
The present invention will be described in detail with reference to examples for further illustration of the invention, but they should not be construed as limiting the scope of the invention.
Example 1
Strain sources: purchasing from national spawn resource center;
strain number/Strain Number CCTCCNF20083277
Chinese Name/Chinese Name Lentinus edodes
Genus name/Genus Lentinul
A preparation method of a Lentinus edodes strain fermentation composition comprises the following steps:
s1, selecting mushroom strain powder according to a corresponding proportion, adding water, dispersing, and inoculating with an inoculum size of 5wt%. Inoculating Lentinus Edodes strain powder dispersion solution, and performing slant culture (the culture process comprises slant culture medium: 10wt% potato+1wt% glucose+0.8wt% peptone+0.1wt% KH 2 PO 4 +0.05wt％MgSQ 4 ·7H 2 O+2wt% agar, pH:5.0-7.5; sterilizing a culture medium: 0.1MPa,20 min; the lentinus edodes strain powder is added with water to disperse and inoculated on a culture medium, and is cultivated for 7 days at a constant temperature of 15 ℃, and then is subjected to shaking culture (shaking culture medium: 1wt% glucose, 0.2wt% peptone, 0.4wt% bran, 0.1wt% KH 2 PO 4 、0.03wt％MgSQ 4 ·7H 2 O, 0.03wt% zinc sulfate, 0.1wt% histidine, 0.05wt% vitamin B1, pH:5.0 to 7.5; inoculating the strain cultured by the inclined plane into a shake flask culture medium under aseptic condition, and culturing for 7 days in a shaking table at 15 ℃ under illumination condition; the oscillating frequency of the reciprocating shaking table is 135 times/min, and red light with the wavelength of 622-760 nm is used for irradiation in the whole shaking flask culture process, and then seed tank culture is carried out (the composition of the culture medium is as follows: 1wt% of hot pressed bean cake powder, 1wt% of glucose, 1wt% of sucrose, 0.1wt% of monopotassium phosphate, 0.05wt% of magnesium sulfate, 0.05wt% of zinc sulfate and 0.1wt% of ammonia groupAcid, 0.02wt% vitamin B1, 0.1wt% soybean oil, 0.05wt% adenine, pH:5.0 to 7.5; under the aseptic condition, inoculating the strain cultured by shaking bottle into a seed tank according to the inoculation amount of 3% by adopting a differential pressure method, and at the temperature of 16 ℃, the tank pressure is 0.02MPa, and the ventilation is 1:0.5 Standing and culturing for 4 days under the condition of (v/v.min); culturing in a propagation tank (the culture medium comprises 1wt% of hot pressed bean cake powder, 1wt% of glucose, 1wt% of sucrose, 0.1wt% of monopotassium phosphate, 0.04wt% of magnesium sulfate, 0.03wt% of zinc sulfate, 0.1wt% of histidine, 0.1wt% of vitamin B1, 0.2wt% of soybean oil, 0.05wt% of adenine and 0.05wt% of uracil, the pH is 5.0-7.5, under aseptic conditions, inoculating the cultured strain in a seed tank into the propagation tank according to the inoculation amount of 9% by adopting a differential pressure method, and standing and culturing for 4 days under the conditions of the temperature of 16 ℃, the tank pressure of 0.02MPa and the ventilation amount of 1:0.15 (v/v.min); culturing in a fermentation tank (the composition of the culture medium of the fermentation tank is 1wt% of hot pressed bean cake powder, 1wt% of glucose, 1wt% of sucrose, 0.2wt% of monopotassium phosphate, 0.04wt% of magnesium sulfate, 0.04wt% of zinc sulfate, 0.2wt% of histidine, 0.2wt% of vitamin B1, 0.2wt% of soybean oil, 0.05wt% of adenine and 0.05wt% of uracil, the pH value is 5.0-7.5; under aseptic condition, inoculating the cultured strain in the propagation tank into the fermentation tank according to the inoculation amount of 5% by adopting a differential pressure method, and culturing for 5 days under the conditions that the temperature is 16 ℃, the tank pressure is 0.02MPa, the ventilation amount is 1:0.75 (v/v.min) and the stirring speed is 40 rpm);
after the fermentation starts, a fermentation broth sample is taken every 22 hours, and the pH value, reducing sugar and amino nitrogen are measured: when the pH is less than 7, the reducing sugar is less than 1.5%, the amino nitrogen is less than 0.4mg/mL, and the bacterial concentration is not less than 14%, the fermentation is finished, and the mushroom strain fermentation culture solution is obtained.
The activity of beta-glucosidase in the mushroom strain fermentation culture solution is 1265U/g, and the strain content is 1.43x10 4 /ml.
S2, selecting linseed concentrated powder (the weight percent of the linseed concentrated powder is water wt% =1:2), red rose powder with heavy petals (the weight percent of the red rose powder with heavy petals is water wt% =1:2), gamma-aminobutyric acid (the weight percent of the gamma-aminobutyric acid is water wt% =1:2), red ginseng powder (the weight percent of the red ginseng powder is water wt% =1:2), red date powder (the weight percent of the red date powder is water wt% =1:2), medlar powder (the weight percent of the medlar powder is water wt% =1:2) and cranberry powder (the weight percent of the cranberry powder is water wt% =1:2), and adding water for dispersion to respectively obtain a linseed dispersion liquid, a red rose dispersion liquid with heavy petals, a gamma-aminobutyric acid dispersion liquid, a red ginseng dispersion liquid, a red date dispersion liquid, a medlar dispersion liquid and a cranberry dispersion liquid;
s3, mixing and uniformly mixing the volume of the mushroom strain fermentation culture solution and the total volume of the flaxseed dispersion liquid, the red rose dispersion liquid with heavy petals, the gamma-aminobutyric acid dispersion liquid, the red ginseng dispersion liquid, the red date dispersion liquid, the medlar dispersion liquid and the cranberry dispersion liquid (the volume ratio of the dispersion liquid is 3:1:1:1:1:1:1) according to the ratio of 9:1, standing at 30 ℃ for 12 hours, centrifuging at 500rpm for 30 minutes to obtain yellow semitransparent supernatant, and drying the supernatant at 85 ℃ for 10 minutes to obtain the mushroom strain fermentation composition.
Example 2
Lentinus edodes strain: purchased from national strain resource library
Strain number/Strain Number CCTCCNF20083277
Chinese Name/Chinese Name Lentinus edodes
Genus name/Genus Lentinul
A preparation method of a Lentinus edodes strain fermentation composition comprises the following steps:
s1, selecting mushroom strain powder according to a corresponding proportion, adding water, dispersing, and inoculating with an inoculum size of 20 wt%. Inoculating Lentinus Edodes strain powder dispersion solution, and culturing with slant culture medium (slant culture medium: 20wt% potato+2wt% glucose+1wt% peptone+0.1wt% KH) 2 PO 4 +0.05wt％MgSQ 4 ·7H 2 O+4wt% agar, pH:5.0-7.5; sterilizing a culture medium: 0.2MPa,30 minutes; the lentinus edodes strain powder is added with water to disperse and inoculated on a culture medium, and is cultivated for 9 days at a constant temperature of 20 ℃, and then is subjected to shaking culture (shaking culture medium: 5wt% glucose, 0.4wt% peptone, 0.6wt% bran, 0.3wt% KH 2 PO 4 、0.05wt％MgSQ 4 ·7H 2 O, 0.05wt% zinc sulfate, 0.3wt% histidine, 0.1wt% vitamin B1, pH:5.0 to 7.5; under aseptic condition, inoculating the above-mentioned slant culture medium into shake flask culture mediumPlacing the cultured strain in a shaking table at a constant temperature of 20 ℃ and culturing for 9 days under illumination; the oscillating frequency of the reciprocating shaking table is 135 times/min, and red light with the wavelength of 622-760 nm is used for irradiation in the whole shaking flask culture process, and then seed tank culture is carried out (the composition of the culture medium is as follows: 2wt% of hot pressed soybean cake powder, 2wt% of glucose, 2wt% of sucrose, 0.2wt% of monopotassium phosphate, 0.05wt% of magnesium sulfate, 0.05wt% of zinc sulfate, 0.1wt% of histidine, 0.02wt% of vitamin B1, 0.1wt% of soybean oil, 0.05wt% of adenine, pH:5.0 to 7.5; under the aseptic condition, inoculating the strain cultured by shaking bottle into a seed tank according to the inoculation amount of 3% by adopting a differential pressure method, and at the temperature of 16 ℃, the tank pressure is 0.02MPa, and the ventilation is 1:0.5 Standing and culturing for 5 days under the condition of (v/v.min); culturing in a propagation tank (the culture medium comprises 2wt% of hot pressed bean cake powder, 2wt% of glucose, 2wt% of sucrose, 0.1wt% of monopotassium phosphate, 0.04wt% of magnesium sulfate, 0.03wt% of zinc sulfate, 0.1wt% of histidine, 0.1wt% of vitamin B1, 0.2wt% of soybean oil, 0.05wt% of adenine and 0.05wt% of uracil, the pH is 5.0-7.5, under aseptic conditions, inoculating the cultured strain in a seed tank into the propagation tank according to the inoculation amount of 9% by adopting a differential pressure method, and standing and culturing for 5 days under the conditions of the temperature of 16 ℃ and the tank pressure of 0.02MPa and the ventilation amount of 1:0.15 (v/v.min); culturing in a fermentation tank (the composition of the culture medium of the fermentation tank is 3wt% of hot pressed bean cake powder, 1wt% of glucose, 1wt% of sucrose, 0.2wt% of monopotassium phosphate, 0.04wt% of magnesium sulfate, 0.04wt% of zinc sulfate, 0.2wt% of histidine, 0.2wt% of vitamin B1, 0.2wt% of soybean oil, 0.05wt% of adenine and 0.05wt% of uracil, the pH value is 5.0-7.5; under the aseptic condition, inoculating the cultured strain in the propagation tank into the fermentation tank according to the inoculation amount of 5% by adopting a differential pressure method, and culturing for 4 days under the conditions that the temperature is 16 ℃, the tank pressure is 0.02MPa, the ventilation amount is 1:0.75 (v/v.min) and the stirring speed is 40 rpm);
after the fermentation is started, a fermentation liquid sample is taken every 24 hours, and the pH value, reducing sugar and amino nitrogen are measured: when the pH is less than 7, the reducing sugar is less than 1.5%, the amino nitrogen is less than 0.4mg/mL, and the bacterial concentration is not less than 14%, the fermentation is finished, and the mushroom strain fermentation culture solution is obtained.
The activity of beta-glucosidase in the mushroom strain fermentation culture solution is 1265U/g, and the bacterial content is 1.4X10 4 /ml.
S2, selecting linseed concentrated powder (the weight percent of the linseed concentrated powder is water wt% =1:4), red rose powder with heavy petals (the weight percent of the red rose powder with heavy petals is water wt% =1:4), gamma-aminobutyric acid (the weight percent of the gamma-aminobutyric acid is water wt% =1:4), red ginseng powder (the weight percent of the red ginseng powder is water wt% =1:4), red date powder (the weight percent of the red date powder is water wt% =1:4), medlar powder (the weight percent of the medlar powder is water wt% =1:4) and cranberry powder (the weight percent of the cranberry powder is water wt% =1:4), and adding water for dispersion to respectively obtain a linseed dispersion liquid, a red rose dispersion liquid, a gamma-aminobutyric acid dispersion liquid, a red ginseng dispersion liquid, a red date dispersion liquid, a medlar dispersion liquid and a cranberry dispersion liquid;
s3, mixing and uniformly mixing the volume of the mushroom strain fermentation culture solution and the total volume of the linseed dispersion liquid, the red rose dispersion liquid, the gamma-aminobutyric acid dispersion liquid, the red ginseng dispersion liquid, the red date dispersion liquid, the medlar dispersion liquid and the cranberry dispersion liquid (3:1:1:1:1:1) according to the ratio of 9:3, standing at 37 ℃ for 16 hours, centrifuging at 600rpm for 30 minutes to obtain a yellow semitransparent supernatant, and drying the supernatant at 130 ℃ for 15 minutes to obtain the mushroom strain fermentation composition.
Experimental example
400 parts of linseed concentrated powder, 200 parts of red rose powder with heavy petals, 200 parts of gamma-aminobutyric acid, 300 parts of red ginseng powder, 300 parts of red date powder, 300 parts of medlar powder, 300 parts of cranberry powder and 600 parts of mushroom strain fermentation liquor (prepared by the preparation method of example 2) are adopted. The lentinus edodes strain fermentation composition obtained by the preparation method of the example 2 is used as an experimental reagent.
Volunteers experience a method of efficacy:
(1) Inclusion criteria: women aged 20-60 years have no obvious history of cardiovascular and cerebrovascular diseases, and no clear diabetic complications.
(2) Dosage for administration: 1-2 bags (2 g/bag) each time, once a day, are recommended for administration after dinner. The administration was continued for 21 days (avoid administration during menstruation).
Table 1 experience results statistics method
Figure BDA0004109853130000131
/>
Figure BDA0004109853130000141
/>
Figure BDA0004109853130000151
Remarks: symptom change condition and outcome determination: and (3) result judgment: no change: no step, e.g., from 2 to 2; improvement: one step up, for example from 1 to 2: the obvious improvement is as follows: stage two, e.g., from 1 to 3. Wherein, Q: representative before taking; h: representative of administration.
Symptom change condition:
menstrual flow: i is absent, II is rare, III is normal, and IV is large.
Menstrual flow properties: 1. dark brown, 2, dark red, 3, bright red, 4, with blood clots.
Menstrual days per month: 1:0,2: < 2 days, 3: day 3, 4: day > 5.
Dysmenorrhea condition: 1: none, 2: mild, 3: moderate, 4: heavy weight.
Emotional state: 1. frequent emotional disturbance, 2. Easy agitation, 3. Emotional stabilization.
Climacteric symptom: flushing, headache, dizziness, tiredness, hypodynamia, sweating and the like: 1. frequently, 2. Less frequently, 3. None.
Sleep state: 1. not easy to fall asleep, 2, easy to wake up, 3, good sleep.
Skin condition: 1. loose and poor elasticity, 2. Plump and good elasticity.
Vaginal lubrication state during sexual life: 1. dry and astringent, 2. Lubricate.
Breast condition: 1. the lobule is proliferated, 2, there is breast nodule, 3, breast drop, 4, it is elastic.
Uterine state: 1. uterine fibroids, 2, endometriosis, 3, no abnormalities.
Results: the lentinus edodes strain fermentation composition provided by the invention has 88% of improvement rate (improvement+obvious improvement) for users, and has the effect of obviously improving female endocrine dyscrasia, so that the syndrome caused by female estrogen reduction is improved.
Materials and methods
Reagent:
analytical grade chemicals such as SECO-DG and SECO were all available from Sigma Ardrich Fine chemical Co., st.Louis, mitsui. Lentinus edodes (CCTCCCF 20081587) was purchased from the national center for microbial resources (Beijing).
Culturing Lentinus Edodes mycelium and measuring beta-glucosidase activity. B-glucosidase activity in lentinus edodes mycelium cultures was monitored daily until beta-glucosidase activity >1200U/g. Measurement of glucosidase activity of cultured Lentinus edodes mycelia: 1ml of acetic buffer (100 mm, pH 5.0) and 0.5ml of phenylnitrobenzene-d-glucoside (6.03 mg/ml, pre-warmed 37C5 min) were added as 0.5ml of sample or standard glucosidase (about 0.01-0.02 IU/ml). After incubating the solution at 37 ℃ for 15min, 2ml of sodium carbonate solution (0.2M) was added to stop the reaction. The absorbance was measured at 400 nm.
Culturing Lentinus Edodes complex containing total SECO-DG and SECO.
The complex containing total SECO-DG (8 mM) was cultured with a beta-glucosidase active mushroom culture containing 1.0% malt extract, 0.125% yeast extract, and 0.1% ammonium tartrate. Inoculating mushroom mycelium to the fungus base, and culturing at 25 deg.C on rotary shaker at 130rpm for 7-14 days. The culture solution containing the fermentation complex and the lentinus edodes mycelium is freeze-dried. 1ml of the medium was collected, mixed with 1ml of ethyl acetate, and SECO was extracted during the culture. SECO in the medium was determined by HPLC.
HPLC analysis of SECO
Instrument assemblies were purchased from hitachi (tokyo). Column: TSK-gel80TM (Tosoh) reverse C18,100A (10 nm), 250X 4.6 mm. The ultraviolet detector was set at 260nm. Initial conditions were 10% acetonitrile: 90% water contained 0.1% acetic acid followed by a linear gradient of 40 minutes to 40% acetic acid contained 0.1% acetonitrile.
Determination of concentration of human urine SECO taken with non-fermented Lentinus Edodes Complex (NFLEC) or Fermented Lentinus Edodes Complex (FLEC)
The effect of single oral NFLEC and FLEC was studied using 8 healthy subjects (4 men and 4 women, between 24-42 years of age, average body weight of 59.4kg, standard deviation of 13.9). All subjects obtained informed consent. At 9:00, subjects receiving NFLEC (n=4) ingest 60mg/kg body weight, subjects receiving or FLEC (n=4) ingest 30mg/kg body weight. Urine samples (2 ml) were collected at 0,1,3,5,7,24 h after consumption. Urine samples were centrifuged at 3000 Xg for 20min at 4℃and analyzed by HPLC.
Urine samples were treated with beta-glucuronidase (Sigma) to convert the glucuronate conjugated form to the aglycone form. To a 0.5ml urine sample, 0.5ml acetate buffer (100 mM, pH 5.0) and 30ml of a solution of glucuronidase were added. After incubation for 1h at 37℃1ml of ethyl acetate was added to extract SECO. The HPLC treatment method is described above.
TABLE 2 comparison of the absorption rate of SECO in urine after 3 hours in the non-fermented intake group (UFLEC) and the fermented composition (FLEC) intake group of healthy subjects
Figure BDA0004109853130000171
Figure BDA0004109853130000181
The absorption of SECO in the 3 hour urine of the unfermented composition administration group was about 15% and the absorption of SECO in the 3 hour urine of the fermented composition administration group was about 75% based on the total SECO-DG content of the composition of 8 mM.
Although the foregoing embodiments have been described in some, but not all, embodiments of the invention, it should be understood that other embodiments may be devised in accordance with the present embodiments without departing from the spirit and scope of the invention.

Claims (10)

1. The mushroom strain fermentation composition is characterized by being prepared from the following raw materials in parts by weight:
20-60 parts of flaxseed concentrated powder, 10-30 parts of red rose with heavy petals, 10-30 parts of gamma-aminobutyric acid, 10-55 parts of red ginseng, 10-55 parts of red date, 10-55 parts of medlar, 10-55 parts of cranberry and 20-100 parts of mushroom strain fermentation culture solution.
2. The lentinus edodes seed fermentation composition according to claim 1, which is prepared from the following raw materials in parts by weight:
30-50 parts of flaxseed concentrated powder, 15-25 parts of red rose with heavy petals, 15-25 parts of gamma-aminobutyric acid, 22-45 parts of red ginseng, 22-45 parts of red date, 22-45 parts of medlar, 22-45 parts of cranberry and 44-80 parts of mushroom strain fermentation culture solution.
3. The lentinus edodes seed fermentation composition according to claim 1, which is prepared from the following raw materials in parts by weight:
40 parts of flaxseed concentrated powder, 20 parts of red rose with heavy petals, 20 parts of gamma-aminobutyric acid, 30 parts of red ginseng, 30 parts of red date, 30 parts of medlar, 30 parts of cranberry and 60 parts of mushroom strain fermentation culture solution.
4. The lentinula edodes seed fermentation composition of claim 1, wherein the red rose flowers are red rose pollen flowers;
the red ginseng is red ginseng powder;
the red dates are red date powder;
the medlar is medlar powder;
the cranberry is cranberry powder;
the fungus content in the Lentinus edodes strain fermentation culture solution is 1x10 4 -1x10 5 /ml.
5. A process for preparing a fermented composition of lentinus edodes seed according to any one of claims 1 to 4, comprising the steps of:
1) Dispersing mushroom strains into water to obtain mushroom strain dispersion liquid, and sequentially carrying out slant culture, shake flask culture, seed culture, propagation culture and fermentation culture on the mushroom strain dispersion liquid to obtain mushroom strain fermentation culture liquid;
2) The linseed concentrated powder, the red rose with heavy petals, the gamma-aminobutyric acid, the red ginseng, the red jujube, the medlar and the cranberry are respectively dispersed in water to obtain a linseed dispersion liquid, a red rose with heavy petals, a gamma-aminobutyric acid dispersion liquid, a red ginseng dispersion liquid, a red jujube dispersion liquid, a medlar dispersion liquid and a cranberry dispersion liquid;
3) Mixing the lentinus edodes strain fermentation culture solution obtained in the step 1) with the flaxseed dispersion liquid, the red rose dispersion liquid with heavy petals, the gamma-aminobutyric acid dispersion liquid, the red ginseng dispersion liquid, the red date dispersion liquid, the medlar dispersion liquid and the cranberry dispersion liquid obtained in the step 2), standing for reaction, centrifuging to obtain a supernatant, and drying the supernatant to obtain the lentinus edodes strain fermentation composition;
the steps 1) and 2) are defined in no time sequence.
6. The method according to claim 5, wherein the conditions for the standing reaction in step 3) include: the temperature is 30-37 ℃ and the time is 12-16 h.
7. The method according to claim 5, wherein the total volume ratio of the fermentation broth of the Lentinus edodes strain in the step 3) to the flaxseed dispersion, the red rose dispersion, the gamma-aminobutyric acid dispersion, the red ginseng dispersion, the red date dispersion, the medlar dispersion and the cranberry dispersion is 9:1-3.
8. The preparation method of claim 5, wherein the mass ratio of the flaxseed concentrate powder, the red rose with heavy petals, the gamma-aminobutyric acid, the red ginseng, the red dates, the medlar, the cranberry and the water in the step 2) is 1:2-4.
9. The preparation method according to claim 5, wherein the activity of beta-glucosidase in the fermentation broth of the Lentinus edodes strain in the step 1) is not less than 1200U/g.
10. Use of a lentinus edodes seed fermentation composition according to any one of claims 1 to 4 for the preparation of a medicament for female endocrine dyscrasia.
CN202310203233.0A 2023-03-06 2023-03-06 Lentinus edodes strain fermentation composition and preparation method and application thereof Pending CN116211938A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202310203233.0A CN116211938A (en) 2023-03-06 2023-03-06 Lentinus edodes strain fermentation composition and preparation method and application thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202310203233.0A CN116211938A (en) 2023-03-06 2023-03-06 Lentinus edodes strain fermentation composition and preparation method and application thereof

Publications (1)

Publication Number Publication Date
CN116211938A true CN116211938A (en) 2023-06-06

Family

ID=86574696

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202310203233.0A Pending CN116211938A (en) 2023-03-06 2023-03-06 Lentinus edodes strain fermentation composition and preparation method and application thereof

Country Status (1)

Country Link
CN (1) CN116211938A (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117898395A (en) * 2024-03-18 2024-04-19 长春中医药大学 Fermented composition and application thereof in preparation of product with bowel relaxing effect

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113730476A (en) * 2021-09-17 2021-12-03 无锡康能特医食品科技有限公司 Paecilomyces hepiali strain fermentation composition and preparation method and application thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113730476A (en) * 2021-09-17 2021-12-03 无锡康能特医食品科技有限公司 Paecilomyces hepiali strain fermentation composition and preparation method and application thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
李大和: "《营养型低度发酵酒生产技术》", 中国轻工业出版社, pages: 185 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117898395A (en) * 2024-03-18 2024-04-19 长春中医药大学 Fermented composition and application thereof in preparation of product with bowel relaxing effect

Similar Documents

Publication Publication Date Title
KR101370386B1 (en) Preparation method of fermented red ginseng using effective micro-organisms
CN106244372B (en) Enzyme-fermented gastrodia elata health-preserving beverage for improving sleep and preparation process and application thereof
US11376292B2 (en) Microbial fermentation composition subjected to enzymolysis, microbial fermentation and microbial transformation and use thereof
CN110354204B (en) Composition with eyesight improving effect and preparation and application methods thereof
KR101331171B1 (en) Fermented-red gingseng or fermented-gingseng containing increased gensenoside rd and methods for preparation of the same
CN113730476A (en) Paecilomyces hepiali strain fermentation composition and preparation method and application thereof
CN105639560A (en) Biological-enzymolysis-method sporoderm-broken lucid ganoderma spore powder honey for calming nerves and aiding sleep and production process thereof
CN116211938A (en) Lentinus edodes strain fermentation composition and preparation method and application thereof
CN113017092A (en) Fermentation type small molecule peptide mixed solution for regulating blood sugar and preparation method and application thereof
CN106387582A (en) Method of preparing enzymes by fermenting cereals
CN107751993A (en) A kind of antifatigue cream taste and preparation method thereof
CN102816667B (en) Ganoderma lucidum polysaccharide nutrition sweet wine and production process
KR101372400B1 (en) A manufacturing method of red ginseng staf4h with enhanced trace ginsenoside
CN105708970B (en) A kind of health food with function of blood sugar reduction
KR20100079874A (en) Preparation method of fermented ginseng or fermented red ginseng with active ginsenoside heightening absroption rate using lactic acid bacteria
CN111700142B (en) Preparation method of fermented poria acid substituted tea
CN103301321A (en) Thrombolytic active polysaccharide mixture preparation technology
CN111264877A (en) Preparation method of medicinal and edible high-fiber functional food
CN110279053A (en) A kind of pectase beverage of rich in nutrition and preparation method thereof
CN103055157A (en) Compound dendrobium huoshanense, cistanche and ganoderma granules and production process thereof
CN113621673B (en) Method for fermenting ginseng by composite strain, fermentation product and application
CN111820401A (en) A method for preparing fermented Ginseng radix powder
KR20120053564A (en) Fermented ginseng with ganoderma lucidum beverage manufacturing method and that beverage
CN113413419A (en) Ovary care composition containing jujube exosome and preparation method thereof
CN113648377A (en) Composition for relieving depression and soothing nerves and preparation method thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination